| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 1.77% |
| NAV | ₹112.46 (03 Jul 2020) |
|---|---|
| Fund Started | 01 Jan 2013 |
| Fund Size | ₹475 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 11.4% |
| Cipla Ltd. | Healthcare | Equity | 9.1% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 8.4% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 7.7% |
| Lupin Ltd. | Healthcare | Equity | 6.7% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 6.2% |
| Biocon Ltd. | Healthcare | Equity | 5.4% |
| Cadila Healthcare Ltd. | Healthcare | Equity | 5.0% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 4.6% |
| Ajanta Pharma Ltd. | Healthcare | Equity | 4.4% |
UTI Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was made available to investors on 01 Jan 2013. V Srivatsa, Ritesh Rathod is the Current Fund Manager of UTI Healthcare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹475 Cr and the Latest NAV as of 03 Jul 2020 is ₹112.46.
The UTI Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed less than 1 year
Aim to invest in companies engaged in the research, manufacture or marketing of OTC products, bulk drugs and formulations
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.